.webp&w=384&q=75){kind=logo}
Loading, please wait...
Loading, please wait...
The Serum Midkine HCC biomarker is transforming the management of liver malignancies, particularly in cases where traditional markers fall short. While alpha-fetoprotein (AFP) remains the standard, it often lacks the sensitivity required for early detection or monitoring AFP-negative patients. Recent clinical studies demonstrate that Midkine offers a more reliable alternative for assessing disease progression and treatment response. Consequently, this biomarker effectively differentiates between benign liver diseases and malignant hepatocellular carcinoma (HCC).
Research indicates that Midkine levels correlate strongly with critical clinicopathological features, including tumor size and Barcelona Clinic Liver Cancer (BCLC) stages. Therefore, higher serum concentrations often signal advanced clinical stages and poor prognosis. Furthermore, clinicians find this marker helpful in characterizing patients who do not show elevated AFP levels. Notably, Midkine’s efficacy in evaluating treatment efficacy is comparable to advanced imaging techniques like CT and MRI. This correlation is particularly beneficial for monitoring patients undergoing non-surgical therapies.
Moreover, multivariate regression models identify Midkine as a key predictive factor for hepatocellular carcinoma. By tracking these levels, healthcare providers can better evaluate the likelihood of disease recurrence or metastasis. Additionally, Midkine levels significantly decrease following successful tumor resection, making it an excellent tool for post-operative surveillance. Therefore, integrating Midkine into routine oncology protocols could lead to more personalized and effective treatment strategies for liver cancer patients.
Midkine exhibits high sensitivity even in patients with normal AFP levels, allowing for the detection and monitoring of HCC cases that might otherwise be missed.
Serum Midkine levels tend to decrease after successful intervention and rise during disease progression, providing a biochemical indicator of treatment efficacy similar to imaging scans.
Disclaimer: This content is for informational and educational purposes only. It is not intended as a substitute for professional medical advice, diagnosis, or treatment. Refer to the latest local and national guidelines for clinical practice.
References
1. Luo Y et al. Serum Midkine as a Biomarker for Hepatocellular Carcinoma Treatment Response and Prognostication. J Clin Lab Anal. 2026 May 25. doi: 10.1002/jcla.70255. PMID: 42184120.
2. Lu Q, et al. Comparison of diagnostic accuracy of Midkine and AFP for detecting hepatocellular carcinoma: a systematic review and meta-analysis. Biosci Rep. 2020;40(3):BSR20192424.
3. Zheng et al. Midkine (MDK) in Hepatocellular Carcinoma: More than a Biomarker. MDPI. 2024;16(2):112.
Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.
Open your smartphone camera to scan and install.
Serum Midkine emerges as a superior biomarker for HCC, specifically in AFP-negative patients, offering high sensitivity for monitoring treatment response....
4 months ago
Discover the crucial role of glymphatic dysfunction in stroke, where perivascular clearance failure and neuroinflammation exacerbate cerebral edema and post-stroke brain injury.
Today
A prenatal case highlights severe glutaric acidemia type II presenting as bilateral hyperechoic cystic kidneys at 18 weeks. Whole-exome sequencing revealed a novel homozygous ETFDH frameshift variant, demonstrating the power of rapid genetic testing in fetal renal anomalies.
Today
Review how tailored exercise programs benefit frail older patients with heart failure. Explore pathophysiological mechanisms, individualized training prescriptions, and strategies to overcome adherence barriers in clinical practice.
Yesterday
This comparative study evaluates posterior labral tears with and without glenohumeral instability, highlighting distinct demographic patterns, MRI underestimation in stable shoulders, and successful arthroscopic repair outcomes.
Yesterday
A clinical study demonstrates that early intervention with tocilizumab, either as monotherapy or bridged with corticosteroids, achieves significant proptosis reduction and resolves active inflammation in treatment-naive thyroid eye disease.
Yesterday
